摘要
目的探讨FOLFOX6方案对进展期胃癌新辅助化疗的临床疗效。方法将2012—2013年我院胃肠外科收治的86例胃癌患者分为两组,对照组46例采用外科手术加辅助化疗,观察组40例采用FOLFOX6为主的新辅助化疗一手术一术后辅助化疗,观察新辅助化疗对进展期胃癌的作用和毒性反应。结果FOLFOX6新辅助化疗组,临床总有效率为50%(20/40)。毒副作用轻,大多数毒性都是I级或者Ⅱ级,无患者因为化疗的不良反应而退出试验;无死亡病例。观察组根治率为82.5%,与对照组的60.8%相比明显增高,P〈0.05;术后并发症发生率并无增加。结论FOL-FOX6新辅助化疗方案能提高进展期胃癌R0切除率,毒性反应较低,不增加手术并发症,是安全有效的方案。
OBJECTIVE To explore the FOLFOX6 scheme the clinical curative effect of new adjuvant chemotherapy for advanced gastric cancer. METHODS 86 patients with gastric cancer from 2012 to 2013 I was admitted to hospital gastrointestinal surgery divided into two groups, a control group of 46 patients using surgery plus adjuvant chemotherapy was observed 40 cases of neoadjuvant chemotherapy using FOLFOX6 based-surgery-surgery adjuvant chemotherapy, ob- served effects and toxicity of neoadjuvant chemotherapy in advanced gastric cancer. RESULTS FOLFOX6 neoadjuvant chemotherapy group, total effective rate was 50%(20/40). Mild side effects, most toxic are Class Ⅰ or Class Ⅱ , no pa tients because of adverse effects of chemotherapy and withdraw from the trial' no deaths. Radical observation group was 82.5%, compared with 60.8% in the control group was significantly higher, P〈0.05;no increase in the incidence of postoperative complications. CONCLUSION FOLFOX6 neoadjuvant chemotherapy can improve advanced gastric R0 re- section rate, low toxicity, no increased surgical complications, is a safe and effective program.
出处
《中华肿瘤防治杂志》
CAS
北大核心
2015年第B11期122-124,共3页
Chinese Journal of Cancer Prevention and Treatment
基金
四川省科技厅基础项目(30504010107
30305030273)
关键词
进展期胃癌
新辅助化疗
手术
奥沙利铂
5-氟尿嘧啶
亚叶酸钙
advanced gastric cancer
neoadjuvant chemotherapy
surgery
oxaliplatin
5-fluorouracil
leucovorin